NovoCure Limited announced that Japan’s MHLW approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. Optune Pax was approved by the U.S. FDA in February 2026 and received a CE Mark in June 2026.
Japan’s approval was based on Phase 3 PANOVA-3, which tested Tumor Treating Fields with those drugs as first-line treatment against the drug combination alone. The trial met its primary endpoint, showing a statistically significant improvement in median overall survival. No new safety signals were observed, and serious adverse events were comparable between arms. Expected device-related skin adverse events under the arrays occurred in 76.3% of treated participants; 21 participants (7.7%) experienced a Grade ≥3 event.
NovoCure Ltd (NVCR) reported that director Timothy Scannell has retired from its Board of Directors, and his board seat was formally vacated in accordance with the company’s Articles of Association effective September 2, 2026.
The company stated that Mr. Scannell’s retirement after five years of service did not result from any disagreement with NovoCure or its management.
NovoCure Ltd (NVCR) reported that in mid-August 2026 it detected unauthorized access to certain information systems at a subsidiary. NovoCure activated its cybersecurity response plan, implemented containment measures, began an internal investigation, and engaged independent cybersecurity forensic experts to review the exposed data.
The review to date found exposure of internal company patient ID numbers for over 1,400 U.S. patient records (without names or other identifying data), additional identifying patient data for fewer than 50 patients in the western U.S., and general contact information for healthcare providers and employees. NovoCure states there was no access to its medical treatment devices, operations were not compromised, and all systems remain fully functional. The company currently does not believe the cybersecurity incident will have a material impact or reasonably likely material impact on its financial condition or results of operations but continues to evaluate the situation and related notification obligations.
Novocure Limited reported second-quarter 2026 net revenues of $183.6 million, a 16% increase year-over-year, with gross margin rising to 78% from 74%. The quarter remained loss-making, with a net loss of $15.7 million or $0.13 per share, but Adjusted EBITDA turned positive at $10.8 million.
Total active patients on Tumor Treating Fields therapy reached 5,128 globally, including 4,636 on Optune Gio, 207 on Optune Lua and 285 on Optune Pax. Cash, cash equivalents and short-term investments totaled $440.6 million as of June 30, 2026, against total liabilities of $457.1 million.
The company received a CE Mark for Optune Pax for locally advanced pancreatic cancer, with Germany as the first launch market, and updated 2026 guidance to $710 million–$725 million in net revenue and $0–$15 million in Adjusted EBITDA. Anticipated Q4 2026 milestones include a U.S. FDA decision on a premarket approval application for brain metastases from non-small cell lung cancer and completion of enrollment in the Phase 3 KEYNOTE D58 glioblastoma trial.
NovoCure Limited reported Q2 2026 net revenues of $183.6 million, up 16% year over year, and first‑half revenues of $357.6 million. Gross margin improved to 78%. Net loss narrowed to $15.7 million in Q2 and $86.8 million for the first half.
Cash, cash equivalents and short‑term investments totaled $440.6 million at June 30, 2026, against $200.0 million of senior secured term debt. Adjusted EBITDA turned positive at $10.8 million in Q2. Active patients on therapy rose to 5,128, driven mainly by Optune Gio.
During the period, the FDA approved Optune Pax for locally advanced pancreatic cancer and a CE certificate was obtained to market it in the EU. The METIS and PANOVA‑4 trials met key endpoints, while the TRIDENT trial in newly diagnosed GBM did not improve overall survival. The company notes it may need to raise additional capital as it expands indications.
NovoCure Ltd reported that its Chief Human Resources Officer, Michal Nath Puri, acquired additional equity through an employee share plan. On June 30, 2026, Puri received 1,905 ordinary shares under the 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, a price determined as 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, as provided by the plan. Following this transaction, Puri directly holds 203,227 ordinary shares of NovoCure. The filing notes that this ESPP transaction is exempt under Rule 16b-3(c), reflecting a routine, compensation-related share acquisition rather than an open-market trade.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X acquired 1,905 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, based on 85% of the closing price on January 1, 2026. Following this ESPP acquisition, he directly holds 461,425 ordinary shares. The transaction is described as exempt under Rule 16b-3(c).
NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.
NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company’s 2025 Employee Share Purchase Plan (ESPP). The shares were purchased for $11.15 per share for the ESPP purchase period from January 1, 2026 through June 30, 2026.
Under the ESPP, the purchase price was set at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, making this a routine compensation-related acquisition rather than an open-market trade. Following this transaction, Danziger directly owns 416,742 ordinary shares.